Volume 22, Number 4—April 2016
Research
Evaluation of Viremia Frequencies of a Novel Human Pegivirus by Using Bioinformatic Screening and PCR
Table 2
Diagnostic method | Diagnoses and characteristics | No. tested | No. (%) HHpgV-1+ | No. (%) HPgV+ |
---|---|---|---|---|
Bioinformatics | ||||
HIV+ | 36 | 0 | 3 (8.3) | |
HIV+/HCV+/PWID | 30 | 0 | 3 (10.0) | |
HCV+/PWID |
120 |
2 (1.7) |
14 (11.6) |
|
PCR | ||||
Hemophilia† | 195 | 1 (0.5) | 18 (9.2) | |
Control group‡ | 50 | 0 | 1 (2.0) |
*HPgV, human pegivirus; HHpgV, human hepegivirus; +, positive;HCV, hepatitis C virus; PWID, persons who inject drugs.
†Previously exposed to virally inactivated factor VIII/IX; all seropositive for HCV.
‡No history of parenteral exposure; HIV-1 and HCV negative.
Page created: March 15, 2016
Page updated: March 15, 2016
Page reviewed: March 15, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.